scispace - formally typeset
Search or ask a question
Institution

Centers for Disease Control and Prevention

GovernmentAtlanta, Georgia, United States
About: Centers for Disease Control and Prevention is a government organization based out in Atlanta, Georgia, United States. It is known for research contribution in the topics: Population & Public health. The organization has 58238 authors who have published 82592 publications receiving 4405701 citations. The organization is also known as: CDC & Centers for Disease Control and Prevention (CDC).


Papers
More filters
Journal ArticleDOI
TL;DR: A framework for the continuum of multidisciplinary translation research that builds on previous characterization efforts in genomics and other areas in health care and prevention is presented and the types of translation research can overlap and provide feedback loops to allow integration of new knowledge.

670 citations

Journal ArticleDOI
15 Aug 1999-Virology
TL;DR: Analysis of the sequences of all eight RNA segments of the influenza A/G oose/Guangdong/1/96 virus revealed that the hemagglutinin (HA) gene of the virus was genetically similar to those of the H5N1 viruses isolated in Hong Kong in 1997, but the remaining genes showed greater similarity to other avian influenza viruses.

670 citations

Journal ArticleDOI
04 Oct 2000-JAMA
TL;DR: Influenza vaccination of healthy working adults younger than 65 years can reduce the rates of ILI, lost workdays, and physician visits during years when the vaccine and circulating viruses are similar, but vaccination may not provide overall economic benefits in most years.
Abstract: ContextAlthough the cost-effectiveness and cost-benefit of influenza vaccination are well established for persons aged 65 years or older, the benefits for healthy adults younger than 65 years are less clear.ObjectiveTo evaluate the effectiveness and cost-benefit of influenza vaccine in preventing influenzalike illness (ILI) and reducing societal costs of ILI among healthy working adults.DesignDouble-blind, randomized, placebo-controlled trial conducted during 2 influenza seasons.Setting and ParticipantsHealthy adults aged 18 to 64 years and employed full-time by a US manufacturing company (for 1997-1998 season, n = 1184; for 1998-1999 season, n = 1191).InterventionsFor each season, participants were randomly assigned to receive either trivalent inactivated influenza vaccine (n = 595 in 1997-1998 and n = 587 in 1998-1999) or sterile saline injection (placebo; n = 589 in 1997-1998 and n = 604 in 1998-1999). Participants in 1997-1998 were rerandomized if they participated in 1998-1999.Main Outcome MeasuresInfluenzalike illnesses and associated physician visits and work absenteeism reported in biweekly questionnaires by all participants, and serologically confirmed influenza illness among 23% of participants in each year (n = 275 in 1997-1998; n = 278 in 1998-1999); societal cost of ILI per vaccinated vs unvaccinated person.ResultsFor 1997-1998 and 1998-1999, respectively, 95% (1130/1184) and 99% (1178/1191) of participants had complete follow-up, and 23% in each year had serologic testing. In 1997-1998, when the vaccine virus differed from the predominant circulating viruses, vaccine efficacy against serologically confirmed influenza illness was 50% (P = .33). In this season, vaccination did not reduce ILI, physician visits, or lost workdays; the net societal cost was $65.59 per person compared with no vaccination. In 1998-1999, the vaccine and predominant circulating viruses were well matched. Vaccine efficacy was 86% (P = .001), and vaccination reduced ILI, physician visits, and lost workdays by 34%, 42%, and 32%, respectively. However, vaccination resulted in a net societal cost of $11.17 per person compared with no vaccination.ConclusionInfluenza vaccination of healthy working adults younger than 65 years can reduce the rates of ILI, lost workdays, and physician visits during years when the vaccine and circulating viruses are similar, but vaccination may not provide overall economic benefits in most years.

670 citations

Journal ArticleDOI
22 Feb 2006-JAMA
TL;DR: The results indicate that these drugs should not be used for the treatment or prophylaxis of influenza in the United States until susceptibility to adamantanes has been reestablished among circulating influenza A isolates.
Abstract: ContextThe adamantanes, amantadine and rimantadine, have been used as first-choice antiviral drugs against community outbreaks of influenza A viruses for many years. Rates of viruses resistant to these drugs have been increasing globally. Rapid surveillance for the emergence and spread of resistant viruses has become critical for appropriate treatment of patients.ObjectiveTo investigate the frequency of adamantane-resistant influenza A viruses circulating in the United States during the initial months of the 2005-2006 influenza season.Design and SettingInfluenza isolates collected from 26 states from October 1 through December 31, 2005, and submitted to the US Centers for Disease Control and Prevention were tested for drug resistance as part of ongoing surveillance. Isolates were submitted from World Health Organization collaborating laboratories and National Respiratory and Enteric Virus Surveillance System laboratories.Main Outcome MeasuresUsing pyrosequencing and confirmatory assays, we identified viruses containing mutations within the M2 gene that are known to confer resistance to both amantadine and rimantadine.ResultsA total of 209 influenza A(H3N2) viruses isolated from patients in 26 states were screened, of which 193 (92.3%) contained a change at amino acid 31 (serine to asparagine [S31N]) in the M2 gene known to be correlated with adamantane resistance. Two of 8 influenza A(H1N1) viruses contained the same mutation. Drug-resistant viruses were distributed across the United States.ConclusionsThe high proportion of influenza A viruses currently circulating in the United States demonstrating adamantane resistance highlights the clinical importance of rapid surveillance for antiviral resistance. Our results indicate that these drugs should not be used for the treatment or prophylaxis of influenza in the United States until susceptibility to adamantanes has been reestablished among circulating influenza A isolates.Published online February 2, 2006 (doi:10.1001/jama.295.8.joc60020).

669 citations

Journal ArticleDOI
16 Sep 1998-JAMA
TL;DR: Among currently active members of 4 Air Force populations, a chronic multisymptom condition was significantly associated with deployment to the GW and veterans who met the case definition had significantly diminished functioning and well-being.
Abstract: Context.—Gulf War (GW) veterans report nonspecific symptoms significantly more often than their nondeployed peers. However, no specific disorder has been identified, and the etiologic basis and clinical significance of their symptoms remain unclear.Objectives.—To organize symptoms reported by US Air Force GW veterans into a case definition, to characterize clinical features, and to evaluate risk factors.Design.—Cross-sectional population survey of individual characteristics and symptoms and clinical evaluation (including a structured interview, the Medical Outcomes Study Short Form 36, psychiatric screening, physical examination, clinical laboratory tests, and serologic assays for antibodies against viruses, rickettsia, parasites, and bacteria) conducted in 1995.Participants and Setting.—The cross-sectional questionnaire survey included 3723 currently active volunteers, irrespective of health status or GW participation, from 4 air force populations.The cross-sectional clinical evaluation included 158 GW veterans from one unit, irrespective of health status.Main Outcome Measures.—Symptom-based case definition; case prevalence rate for GW veterans and nondeployed personnel; clinical and laboratory findings among veterans who met the case definition.Results.—We defined a case as having 1 or more chronic symptoms from at least 2 of 3 categories (fatigue, mood-cognition, and musculoskeletal). The prevalence of mild-to-moderate and severe cases was 39% and 6%, respectively, among 1155 GW veterans compared with 14% and 0.7% among 2520 nondeployed personnel. Illness was not associated with time or place of deployment or with duties during the war. Fifty-nine clinically evaluated GW veterans (37%) were noncases, 86 (54%) mild-to-moderate cases, and 13 (8%) severe cases. Although no physical examination, laboratory, or serologic findings identified cases, veterans who met the case definition had significantly diminished functioning and well-being.Conclusions.—Among currently active members of 4 Air Force populations, a chronic multisymptom condition was significantly associated with deployment to the GW. The condition was not associated with specific GW exposures and also affected nondeployed personnel.

668 citations


Authors

Showing all 58382 results

NameH-indexPapersCitations
Graham A. Colditz2611542256034
David J. Hunter2131836207050
Bernard Rosner1901162147661
Richard Peto183683231434
Aaron R. Folsom1811118134044
Didier Raoult1733267153016
James F. Sallis169825144836
David R. Jacobs1651262113892
Steven N. Blair165879132929
Gordon J. Freeman164579105193
Dennis R. Burton16468390959
Rory Collins162489193407
Ali H. Mokdad156634160599
Caroline S. Fox155599138951
Paul Elliott153773103839
Network Information
Related Institutions (5)
University of Maryland, Baltimore
64.7K papers, 2.9M citations

90% related

Emory University
122.4K papers, 6M citations

89% related

University of Alabama at Birmingham
86.7K papers, 3.9M citations

89% related

University of Colorado Denver
57.2K papers, 2.5M citations

89% related

University of North Carolina at Chapel Hill
185.3K papers, 9.9M citations

88% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202327
2022254
20215,505
20205,426
20194,527
20184,344